| Nilvadipine | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Nilvadipine | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
| Nilvadipine | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 4.32E-02 | 1 | Q9Y2C2 | UST | More | |
| Nilvadipine | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
| Nilvadipine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 1.34E-02 | 2 | P06865, Q9H4F1 | HEXA, ST6GALNAC4 | More | |
| Nilvadipine | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Nilvadipine | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
| Nilvadipine | hsa03010 | Ribosome | 1.03E-02 | 2 | P46777, P50914 | RPL5, RPL14 | More | |
| Nilvadipine | hsa04064 | NF-kappa B signaling pathway | 4.58E-03 | 4 | Q13489, Q13546, Q9UDY8, Q9UNE0 | BIRC3, RIPK1, MALT1, EDAR | More | |
| Nilvadipine | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | |
| Nilvadipine | hsa04150 | mTOR signaling pathway | 7.19E-03 | 3 | Q9NQL2, Q13322, Q93098 | RRAGD, GRB10, WNT8B | More | |
| Nilvadipine | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
| Nilvadipine | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | |
| Nilvadipine | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
| Nilvadipine | hsa04217 | Necroptosis | 2.93E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
| Nilvadipine | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
| Nilvadipine | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
| Nilvadipine | hsa04610 | Complement and coagulation cascades | 4.69E-03 | 1 | P0C0L4 | C4A | More | |
| Nilvadipine | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | |
| Nilvadipine | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
| Nilvadipine | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Nilvadipine | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Nilvadipine | hsa04657 | IL-17 signaling pathway | 3.31E-02 | 3 | P49841, P14780, P01375 | GSK3B, MMP9, TNF | More | |
| Nilvadipine | hsa04659 | Th17 cell differentiation | 3.17E-02 | 3 | P25963, P84022, Q13485 | NFKBIA, SMAD3, SMAD4 | More | |
| Nilvadipine | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
| Nilvadipine | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
| Nilvadipine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Nilvadipine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Nilvadipine | hsa04975 | Fat digestion and absorption | 9.50E-04 | 1 | O14494 | PLPP1 | More | |
| Nilvadipine | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | |
| Nilvadipine | hsa05132 | Salmonella infection | 5.76E-04 | 7 | P25963, Q13546, Q13489, P10415, Q9BQS8, O60282, P68371 | NFKBIA, RIPK1, BIRC3, BCL2, FYCO1, KIF5C, TUBB2C | More | |
| Nilvadipine | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
| Nilvadipine | hsa05150 | Staphylococcus aureus infection | 4.36E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | |
| Nilvadipine | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | |
| Nilvadipine | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Nilvadipine | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | |
| Nilvadipine | hsa05214 | Glioma | 4.10E-02 | 2 | P09619, Q02750 | PDGFRB, MAP2K1 | More | |
| Nilvadipine | hsa05218 | Melanoma | 1.34E-02 | 2 | P09619, Q02750 | PDGFRB, MAP2K1 | More | |
| Nilvadipine | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | |
| Nilvadipine | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
| Nilvadipine | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Nilvadipine | hsa05230 | Central carbon metabolism in cancer | 4.10E-02 | 2 | P09619, Q02750 | PDGFRB, MAP2K1 | More | |
